Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PFE

Pfizer Seeks Expanded Use Approval For Breast Cancer Drug

Pfizer Inc. (NYSE:PFE) on Tuesday announced the initial results from a clinical trial called HER2CLIMB-05.

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Why AbbVie and Johnson & Johnson Could Outperform Pfizer

Pfizer stock is moving higher after being named part of the TrumpRx platform; but two other biopharma companies may offer better long-term growth potential

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

TrumpRx Brings Pfizer Into the Green—Is It a Buy?

Pfizer entered into a major agreement with the U.S. government to produce more affordable drugs for Americans. However, the stock’s outlook is still cloudy.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Votes of confidence: Which political groups will defend von der Leyen?

The European Commission is set to survive the two motions of censure to be voted on Thursday. But its support could shrink even more.

Trump’s Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

Trump’s drug price plan drove a Pfizer rally, leaves Eli Lilly buffered by U.S. investments, and could boost JNJ if it secures similar tariff relief.

Top 3 Dividend Achievers for October: High Yields, Growth Ahead

High-yield Dividend Achievers, such as United Parcel Service, Verizon, and Pfizer, offer attractive entry points in October for income investors.

Pfizer Shares Are Trading Higher Wednesday: What's Going On?

Pfizer (NYSE:PFE) shares are trading higher Wednesday after President Donald Trump announced a drug-pricing deal with the company.

inkl

Read news from The Economist, FT, and more,
with one subscription

Stock Of The Day: Will Pfizer Head Higher?

Shares of Pfizer Inc. (NYSE:PFE) continue to head higher on Wednesday, a day after the company announced that it has secured a three-year grace period from President Donald Trump's tariffs on pharmaceuticals. This will enable Pfizer to offer its medication at significantly discounted prices compared to current rates.

Pfizer's TrumpRx Pact Sends Shockwaves: Why UnitedHealth, Lilly And CVS Can't Look Away

Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a…

Lithium Americas, Nike, Pfizer, CoreWeave And Occidental Petroleum: Why These 5 Stocks Are On Investors' Radars Today

Lithium Americas, Nike, Pfizer, CoreWeave And Occidental Petroleum: Why These 5 Stocks Are On Investors' Radars Today

The U.S. stock market brushed aside worries over a potential government shutdown and advanced on Tuesday. The Dow Jones Industrial Average gained nearly 0.2% to 46,397.89, the SP 500 climbed about 0.4% to 6,688.46, and the Nasdaq rose 0.3% to 22,660.These are the top stocks that gained the attention of…

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk

The U.S. pharmaceutical industry is at the center of a policy maelstrom. President Donald Trump on Sep 25, put a 100% tariff on imported branded and patented medicines starting from Oct 1 with threats that tariffs might go up to as much as 250% in future. The instant market impact…

Pfizer Faces Court Over Depo-Provera Brain Tumor Claims

Pfizer Inc. (NYSE: PFE) faces mounting legal challenges over claims that its contraceptive injection Depo-Provera (DMPA) is linked to brain tumors, with a key court hearing set for late September that could determine whether affected women can pursue their cases in court.

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel'

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current medical recommendations.

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal

Pfizer Inc. (NYSE:PFE) on Monday agreed to acquire Metsera, Inc. (NASDAQ:MTSR) to accelerate the next generation of medicines for obesity and cardiometabolic diseases.

Get all your
news in one place.

100’s of premium titles.
One news app.

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Patriots for Europe submit no-confidence motion against the European Commission

The Eurosceptic group has collected enough signatures to kick off a motion of censure. Von der Leyen will face Parliament’s verdict in October.

Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults.

Fresh no-confidence votes stalk EU's Ursula von der Leyen

The radical Left and far-right are about to present two different motions of censure against the Commission. A first vote is expected in October.

Get all your
news in one place.

100’s of premium titles.
One news app.

European Parliament seeks recovery from Patriots of EU funds misused by previous far-right group

The group that includes France’s Rassemblement National, Italy’s The League, and Hungary’s Fidesz could be obliged to repay over €4 million.

Is Pfizer Stock Underperforming the Nasdaq?

Although Pfizer has underperformed the Nasdaq recently, analysts remain moderately optimistic about the stock’s prospects.

Bernie Sanders Demands Health Secretary RFK Jr.'s Resignation As CDC Leadership Crisis Deepens

Senator Bernie Sanders (I-VT) called for Health and Human Services Secretary Robert F. Kennedy Jr.‘s resignation on Saturday, citing Kennedy’s “dangerous policies” that are “endangering the health of the American people.”

RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines

Health and Human Services Secretary Robert F. Kennedy Jr. announced on social media that the emergency use authorizations for COVID-19 vaccines have now been rescinded.

Unusual Put Option Activity in Pfizer Stock - Have Investors Turned Bearish?

Barchart reports that Pfizer stock is showing unusual put option activity in yesterday's trading. Does that mean investors have turned bearish? Not necessarily, especially given the company's upgraded guidance.

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease

Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle cell disease.

3 Long-Term Dividend Buys You Can Get for Under $50

Discover three undervalued dividend stocks under $50 that offer income, growth potential, and strong total returns for value investors

People

147,491 stories

Robert F. Kennedy Jr

Ursula von der Leyen

Elizabeth Warren

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

the European Commission

European Parliament

the European Parliament

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Government Shutdown

Dow Jones Industrial Average

Sickle Cell Disease

Places

313,371 stories

Washington D.C.

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play